Search Results

Press Releases

Exelixis Announces Update on Second Patent Litigation Trial with MSN Laboratories

October 15, 2024

·

4 min read

Biotech Bay

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May 2024

Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in May.

May 7, 2024

·

2 min read

Policy

Exelixis Announces Settlement of CABOMETYX® (cabozantinib) Patent Litigation with Cipla Limited and Cipla USA

Exelixis, Inc. (Nasdaq: EXEL) today announced that it has entered into a Settlement and License Agreement (Agreement) with Cipla Ltd. and Cipla USA, Inc. (collectively Cipla).

May 20, 2024

·

3 min read

Business

Exelixis to Release Third Quarter 2024 Financial Results on Tuesday, October 29, 2024

October 15, 2024

·

1 min read

Biotech Bay

Exelixis to Present at the William Blair 44th Annual Growth Stock Conference

Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in a fireside chat at the William Blair 44th Annual Growth Stock Conference on Tuesday, June 4 at 4:20 p.m. ET / 3:20 p.m. CT / 1:20 p.m. PT in Chicago.

May 28, 2024

·

1 min read

Business

Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones.

April 30, 2024

·

21 min read

Business

Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024

Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2024 financial results will be released on Tuesday, April 30, 2024 after the markets close.

April 16, 2024

·

1 min read

Biotech Bay

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February 2024

Exelixis, Inc. announced that members of the company’s management team will participate in fireside chats at the following investor conferences in February.

February 1, 2024

·

1 min read

News

Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma

October 14, 2024

·

19 min read

Biotech Bay

Exelixis 2023 R&D Day: Science & Strategy to be Webcast on December 12, 2023

Exelixis, Inc. announced that it will webcast the Exelixis 2023 R&D Day: Science & Strategy event taking place on Tuesday, December 12, 2023, from 9:00 a.m. to 12:30 p.m. EST.

December 7, 2023

·

1 min read